Business
Moderna Tumbles After Nonpartisan Pledge, First Sell Rating – Bloomberg
Moderna Inc. fell 13% on Tuesday after regulators and top drugmakers promised the Covid-19 vaccine approval process would be immune from political pressure and the biotech company drew its first sell rating since going public in 2018.
Moderna Inc. fell 13% on Tuesday after regulators and top drugmakers promised the Covid-19 vaccine approval process would be immune from political pressure and the biotech company drew its first sell rating since going public in 2018.
Moderna’s vaccine is one of three leading candidates Wall Street expects may win an emergency use authorization near-term.. But pledges from the Food and Drug Administration and industry leaders have cast a pall over the prospects of a vaccine being approved befor…
-
Noosa News14 hours agoPill checking to resume in Queensland months after government axed funding
-
Business17 hours agoWhy Austal, Boss Energy, Harvey Norman, and NextDC shares are charging higher today
-
Business17 hours agoWhy Lynas, Mesoblast, PEXA, and Sayona Mining shares are tumbling today
-
Noosa News22 hours agoBob Katter threatens to punch Nine reporter Josh Bavas during anti-immigration press conference